Gilead Sciences Inc (GILD): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Gilead ( GILD) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 2.1%. By the end of trading, Gilead rose $1.81 (2.3%) to $80.67 on average volume. Throughout the day, 10,148,610 shares of Gilead exchanged hands as compared to its average daily volume of 10,868,100 shares. The stock ranged in a price between $79.82-$81.17 after having opened the day at $80.60 as compared to the previous trading day's close of $78.86. Other companies within the Drugs industry that increased today were: Idenix Pharmaceuticals ( IDIX), up 17.0%, SciClone Pharmaceuticals ( SCLN), up 16.7%, Alimera ( ALIM), up 14.0% and Arrowhead Research Corporation ( ARWR), up 13.6%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $123.6 billion and is part of the health care sector. The company has a P/E ratio of 44.3, above the S&P 500 P/E ratio of 17.7. Shares are up 5.0% year to date as of the close of trading on Monday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, iBio ( IBIO), down 7.0%, ProPhase Labs ( PRPH), down 6.7%, Mirati Therapeutics ( MRTX), down 6.1% and Aerie Pharmaceuticals ( AERI), down 5.8% , were all laggards within the drugs industry with Biomarin Pharmaceutical ( BMRN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

These Stocks Pay You to Own Them

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition